Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company has a collaboration with Charles River Laboratories for the development of next-generation multivalent enterovirus vaccines, enhance global regulatory readiness, and support IND-enabling non-clinical studies. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.
Часто задаваемые вопросы
В каком секторе работает Medigen Vaccine Biologics (6547)?
Medigen Vaccine Biologics относится к сектору Здравоохранение.
Какова текущая цена акций Medigen Vaccine Biologics (6547)?
По последним данным, цена акций Medigen Vaccine Biologics составляет 59,70 NT$, предыдущее закрытие — 59,70 NT$.
Выплачивает ли Medigen Vaccine Biologics (6547) дивиденды?
Нет, Medigen Vaccine Biologics не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Medigen Vaccine Biologics (6547)?
У компании Medigen Vaccine Biologics бета -0.060, что указывает на более низкую волатильность по сравнению с рынком в целом.
